---
title: "Opdivo (nivolumab) in metastatic non-small cell lung cancer: Clinical trials questions"
description: "Clinical trials questions on Opdivo (nivolumab) in metastatic non-small cell lung cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Subgroup results, Comparisons, and Long-term results. Questions: Does Opdivo plus Yervoy help patients live longer than chemotherapy (Checkmate 227)? What was progression-free survival with Opdivo plus Yervoy in Checkmate 227? What response rate did Opdivo plus Yervoy achieve in Checkmate 227? How was the Opdivo plus Yervoy Checkmate 227 trial designed? 11 further questions follow. 15 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab) in metastatic non-small cell lung cancer: Clinical trials questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)

Questions that apply to every indication of Opdivo are on [Opdivo (nivolumab), all indications](https://www.evicenter.com/medical-information/opdivo).

## Study results

<a id="opdivo-checkmate-227-survival"></a>

### Does Opdivo plus Yervoy help patients live longer than chemotherapy (Checkmate 227)?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “<sup>§</sup>Median OS: Primary analysis (minimum follow-up 29.3 months): OPDIVO IV + YERVOY IV (n=396): 17.1 mos (95% CI: 15.0–20.1); chemo (n=397): 14.9 mos (95% CI: 12.7–16.7); HR=0.79 (95% CI: 0.67–0.94; P=0.0066).<sup>1,3</sup> 6-year follow-up analysis for OS (minimum/median follow-up: 73.5/78.8 months): OPDIVO IV + YERVOY IV (n=80): 22%; chemo (n=45): 13%; HR=0.78 (95% CI: 0.67–0.91).<sup>2</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=OS%3A%20Primary%20analysis%20%28minimum%20follow%2Dup,%28n%3D45%29%3A%2013%25%3B%20HR%3D0.78%20%2895%25%20CI%3A)

> “Limitation: The 6-year follow-up analysis (median follow-up, 78.8 months) was not statistically powered to detect differences between treatment arms.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Limitation%3A%20The%206%2Dyear%20follow%2Dup%20analysis,detect%20differences%20between%20treatment%20arms.)

Note: Results are from Checkmate 227 Part 1a: first-line treatment in patients with PD-L1 ≥1%.

<a id="opdivo-checkmate-227-progression"></a>

### What was progression-free survival with Opdivo plus Yervoy in Checkmate 227?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “Median PFS, with a minimum follow-up of 73.5 months, was 5.1 months (95% CI: 4.1–6.3) with OPDIVO IV + YERVOY IV and 5.6 months (95% CI: 4.6–5.8) with chemo; 0.80 (95% CI: 0.68–0.94)<sup>2,5‡</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Median%20PFS%2C%20with%20a%20minimum,with%20chemo%3B%200.80%20%2895%25%20CI%3A)

> “<sup>‡</sup>In Checkmate 227 Part 1a, PFS, ORR, and DOR were pre-specified descriptive analyses. The primary efficacy outcome measure was OS.<sup>1,7</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Checkmate%20227%20Part%201a%2C%20PFS%2C,primary%20efficacy%20outcome%20measure%20was)

Note: Results are from Checkmate 227 Part 1a: first-line treatment in patients with PD-L1 ≥1%.

<a id="opdivo-checkmate-227-response"></a>

### What response rate did Opdivo plus Yervoy achieve in Checkmate 227?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “ORR, with a minimum follow-up of 73.5 months, was 36% (n=144/396; CR=6.8%, PR=29.5%) with OPDIVO IV + YERVOY IV and 30% (n=118/397; CR=2.0%, PR=27.7%) with chemo<sup>2,5</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=ORR%2C%20with%20a%20minimum%20follow%2Dup,30%25%20%28n%3D118%2F397%3B%20CR%3D2.0%25%2C%20PR%3D27.7%25%29%20with)

> “mDOR, with a minimum follow-up of 73.5 months, was 24.5 months (95% CI: 15.5–34.5) with OPDIVO IV + YERVOY IV and 6.7 months (95% CI: 5.6–7.6) with chemo<sup>2</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=mDOR%2C%20with%20a%20minimum%20follow%2Dup,months%20%2895%25%20CI%3A%205.6%E2%80%937.6%29%20with)

> “<sup>‡</sup>In Checkmate 227 Part 1a, PFS, ORR, and DOR were pre-specified descriptive analyses. The primary efficacy outcome measure was OS.<sup>1,7</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Checkmate%20227%20Part%201a%2C%20PFS%2C,primary%20efficacy%20outcome%20measure%20was)

Note: Results are from Checkmate 227 Part 1a: first-line treatment in patients with PD-L1 ≥1%.

<a id="opdivo-checkmate-9la-survival"></a>

### Does Opdivo plus Yervoy and chemo improve survival (Checkmate 9LA)?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “At the initial pre-specified interim analysis in the ITT population at the 8.1-month minimum follow-up, the median OS was 14.1 months (95% CI: 13.2–16.2) with OPDIVO + YERVOY with chemo and 10.7 months (95% CI: 9.5–12.5) with chemo alone; HR=0.69 (96.71% CI: 0.55–0.87); P=0.0006<sup>1,3</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=At%20the%20initial%20pre%2Dspecified%20interim%20analysis%20in%20the%20ITT%20population,alone%3B%20HR%3D0.69%20%2896.71%25%20CI%3A%200.55%E2%80%930.87%29%3B)

> “At the 68.6-month minimum follow-up analysis in the ITT population, median OS was 15.8 months (95% CI: 13.9–19.7) with OPDIVO + YERVOY with chemo and 11.0 months (95% CI: 9.5–12.7) with chemo; HR=0.74 (95% CI: 0.63–0.87)<sup>2</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=At%20the%2068.6%2Dmonth%20minimum%20follow%2Dup%20analysis%20in,with%20chemo%3B%20HR%3D0.74%20%2895%25%20CI%3A)

> “Limitation: The 6-year follow-up analysis (median follow-up, 75.8 months) was not statistically powered to detect differences between treatment arms.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=Limitation%3A%20The%206%2Dyear%20follow%2Dup%20analysis,detect%20differences%20between%20treatment%20arms.)

<a id="opdivo-checkmate-9la-progression"></a>

### Does Opdivo plus Yervoy and chemotherapy delay progression (Checkmate 9LA)?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “Median PFS in the ITT population at the 68.6-month minimum follow-up was 6.7 months (95% CI: 5.6–8.0) with OPDIVO + YERVOY with chemo and 5.3 months (95% CI: 4.4–5.6) with chemo; HR=0.70 (95% CI: 0.59–0.82)<sup>2</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=Median%20PFS%20in%20the%20ITT,with%20chemo%3B%20HR%3D0.70%20%2895%25%20CI%3A)

<a id="opdivo-checkmate-9la-response"></a>

### What response rate did Opdivo plus Yervoy and chemotherapy achieve (Checkmate 9LA)?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “ORR in the ITT population at the 68.6-month minimum follow-up was 38% (95% CI: 33–43) with OPDIVO + YERVOY with chemo and 25% (95% CI: 21–30) with chemo<sup>2,5</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=ORR%20in%20the%20ITT%20population,25%25%20%2895%25%20CI%3A%2021%E2%80%9330%29%20with)

> “At the 68.6-month minimum follow-up in the ITT population, 19% of patients were still in response in the OPDIVO + YERVOY with chemo arm (median DOR of 13.0 months [95% CI: 8.7–20.2]). All patients with continuing response in the chemo arm were censored prior to 72 months, so response rate is not available (median DOR of 5.6 months [95% CI: 4.4–7.1])<sup>2</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=At%20the%2068.6%2Dmonth%20minimum%20follow%2Dup%20in,of%205.6%20months%20%5B95%25%20CI%3A)

<a id="opdivo-checkmate-057-017-response"></a>

### What response rates did Opdivo achieve vs docetaxel in previously treated NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

> “<sup>§</sup>In Checkmate 057, the ORR was 19% (56/292; 4 CRs) (95% CI: 15–24) with OPDIVO vs 12% (36/290; 1 CR) (95% CI: 9–17) with docetaxel; P=0.02. The median duration of response was 17 months in the OPDIVO arm (95% CI: 8.4–NR) and 6 months in the docetaxel arm (95% CI: 4.4–7.0).<sup>1</sup> In Checkmate 017, the ORR was 20% (27/135; 1 CR) (95% CI: 14–28) with OPDIVO vs 9% (12/137; 0 CRs) (95% CI: 5–15) with docetaxel; P=0.0083.<sup>1</sup> The median duration of response was NR months in the OPDIVO arm (95% CI: 9.8–NR) and 8.4 months in the docetaxel arm (95% CI: 3.6–10.8).<sup>1</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy?tabKey=oivcheckmate057and017#:~:text=Checkmate%20057%2C%20the%20ORR%20was,8.4%20months%20in%20the%20docetaxel%20arm%20%2895%25%20CI%3A)

<a id="opdivo-checkmate-057-017-progression"></a>

### What was progression-free survival with Opdivo vs docetaxel in previously treated NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

> “mPFS was 2.3 months with OPDIVO IV vs 4.2 months with docetaxel; HR=0.92 (95% CI: 0.77–1.11); P=0.39”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy?tabKey=oivcheckmate057and017#:~:text=mPFS%20was%202.3%20months%20with,HR%3D0.92%20%2895%25%20CI%3A%200.77%E2%80%931.11%29%3B%20P%3D0.39)

> “mPFS was 3.5 months with OPDIVO IV vs 2.8 months with docetaxel; HR=0.62 (95% CI: 0.47–0.81); P=0.0004”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy?tabKey=oivcheckmate057and017#:~:text=mPFS%20was%203.5%20months%20with,HR%3D0.62%20%2895%25%20CI%3A%200.47%E2%80%930.81%29%3B%20P%3D0.0004)

Note: The first result is from Checkmate 057 (non-squamous) and the second from Checkmate 017 (squamous), as labeled on the efficacy page.

## Clinical trials

<a id="opdivo-checkmate-227-design"></a>

### How was the Opdivo plus Yervoy Checkmate 227 trial designed?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “Study design: Checkmate 227 was a randomized, open-label, phase 3 trial in patients with metastatic or recurrent NSCLC. Key eligibility criteria included patients 18 years or older, stage IV or recurrent NSCLC, ECOG PS 0/1, and no prior systemic anticancer therapy. Patients with known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, untreated brain metastases, carcinomatous meningitis, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the study. Treatment continued until disease progression, unacceptable toxicity, or for up to 24 months. Tumor specimens were evaluated prospectively using the PD-L1 IHC 28-8 pharmDx assay at a central laboratory. In Part 1a (n=793), patients with PD-L1 ≥1% were randomized to either OPDIVO IV 3 mg/kg q2w<sup>§</sup> + YERVOY IV 1 mg/kg q6w (n=396) or platinum-doublet chemotherapy* (n=397). The primary endpoint in Part 1a was OS in patients with PD-L1 ≥1%. Pre-specified descriptive efficacy measures included PFS, ORR, and DOR.<sup>1,6</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Study%20design%3A%20Checkmate%20227%20was,measures%20included%20PFS%2C%20ORR%2C%20and)

> “*Vs chemo. In Checkmate 227, patients in the comparator arm received up to 4 cycles of platinum-doublet chemo q3w; NSQ: pemetrexed + carboplatin or cisplatin, with optional pemetrexed maintenance following chemo; SQ: gemcitabine + carboplatin or cisplatin.<sup>1,7</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=%2AVs%20chemo.%20In%20Checkmate%20227%2C,SQ%3A%20gemcitabine%20%2B%20carboplatin%20or)

> “29% of patients enrolled had SQ disease; 71% had NSQ disease<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=29%25%20of%20patients%20enrolled%20had%20SQ%20disease%3B%2071%25%20had%20NSQ)

<a id="opdivo-checkmate-9la-design"></a>

### How was the Checkmate 9LA trial of Opdivo, Yervoy, and chemotherapy designed?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “Study design: Checkmate 9LA was a randomized (1:1), open-label, phase 3 study of OPDIVO 360 mg q3w in combination with YERVOY 1 mg/kg q6w and 2 cycles of histology-based chemotherapy vs 4 cycles of platinum-doublet chemotherapy* as a first-line treatment in patients with metastatic or recurrent NSCLC regardless of histology or PD-L1 status. Key eligibility criteria included patients 18 years or older, stage IV or recurrent NSCLC, ECOG PS 0/1 and no prior systemic anticancer therapy. Patients with known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, untreated brain metastases, carcinomatous meningitis, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the study. Treatment continued until disease progression, unacceptable toxicity, or for up to 2 years. Patients were stratified by histology (SQ vs NSQ), PD-L1 (<1% vs ≥1%), and sex. The primary endpoint was OS. Additional efficacy outcome measures were PFS, ORR, and DOR.<sup>1,5</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=Study%20design%3A%20Checkmate%209LA%20was,measures%20were%20PFS%2C%20ORR%2C%20and)

> “*In Checkmate 9LA, patients received 2 cycles of platinum-doublet chemo q3w in the experimental arm, and 4 cycles in the comparator arm; NSQ: pemetrexed + carboplatin or cisplatin (optional pemetrexed maintenance therapy in the comparator arm only); SQ: paclitaxel + carboplatin.<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=%2AIn%20Checkmate%209LA%2C%20patients%20received,comparator%20arm%20only%29%3B%20SQ%3A%20paclitaxel)

> “37% of patients enrolled had PD-L1 expression of <1%; 24% had PD-L1 expression of ≥50%<sup>7</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=37%25%20of%20patients%20enrolled%20had,24%25%20had%20PD%2DL1%20expression%20of)

<a id="opdivo-checkmate-057-017-design"></a>

### How were the Opdivo Checkmate 057 and 017 trials designed?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

> “Study design: Checkmate 057 (NSQ) and Checkmate 017 (SQ) mNSCLC study designs: Two registrational, phase 3, randomized (1:1), open-label studies, separated by histology, of OPDIVO 3 mg/kg IV over 60 minutes q2w<sup>‡</sup> (n=292 for Checkmate 057; n=135 for Checkmate 017) vs docetaxel 75 mg/m<sup>2</sup> q3w (n=290 for Checkmate 057; n=137 for Checkmate 017) in patients with mNSCLC who had experienced disease progression on or after one prior platinum-based chemotherapy regimen and appropriate targeted therapy in patients with known sensitizing EGFR mutation or ALK translocation. The primary endpoint for both studies was OS; secondary endpoints included ORR and PFS.<sup>1,7,8</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy?tabKey=oivcheckmate057and017#:~:text=Study%20design%3A%20Checkmate%20057%20%28NSQ%29,secondary%20endpoints%20included%20ORR%20and)

<a id="opdivo-qvantig-supporting-evidence"></a>

### What evidence supports Opdivo Qvantig for previously treated metastatic NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “*OPDIVO Qvantig was not evaluated in Checkmate 057 or Checkmate 017. The use of OPDIVO Qvantig is supported by the pivotal trials of OPDIVO IV and Checkmate 67T. In Checkmate 67T, OPDIVO Qvantig demonstrated noninferiority to OPDIVO IV with a comparable PK and ORR profile. OPDIVO Qvantig is not indicated in combination with ipilimumab.<sup>3,4</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy#:~:text=%2AOPDIVO%20Qvantig%20was%20not%20evaluated,not%20indicated%20in%20combination%20with)

> “The use of OPDIVO Qvantig in previously treated metastatic NSCLC is supported by the pivotal trials Checkmate 057 and 017 of OPDIVO IV and comparable PK profile of Checkmate 67T.<sup>a</sup>*”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy#:~:text=The%20use%20of%20OPDIVO%20Qvantig%20in,comparable%20PK%20profile%20of%20Checkmate)

Note: Checkmate 67T enrolled adults with previously treated advanced or metastatic clear cell renal cell carcinoma.

## Subgroup results

<a id="opdivo-checkmate-9la-pd-l1-below-1"></a>

### Opdivo plus Yervoy and chemo at PD-L1 below 1%: Checkmate 9LA results?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “At the 68.6-month minimum follow-up analysis in patients with PD-L1 <1%, median OS was 17.7 months (95% CI: 13.7–20.3) with OPDIVO + YERVOY with chemo and 9.8 months (95% CI: 7.7–13.5) with chemo; HR=0.64 (95% CI: 0.49–0.84)<sup>2</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=At%20the%2068.6%2Dmonth%20minimum%20follow%2Dup%20analysis%20in%20patients,with%20chemo%3B%20HR%3D0.64%20%2895%25%20CI%3A)

> “At the 68.6-month minimum follow-up in patients with PD-L1 <1%, ORR was 31% (42/135) with OPDIVO + YERVOY with chemo and 20% (26/129) with chemo<sup>2</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=At%20the%2068.6%2Dmonth%20minimum%20follow%2Dup%20in%20patients%20with%20PD%2DL1%20%3C1%25%2C,chemo%20and%2020%25%20%2826%2F129%29%20with)

> “Checkmate 9LA was not powered to detect differences in the treatment effect in PD-L1 subgroups; therefore, results from this exploratory analysis should be interpreted with caution because of the limited patient numbers and potential imbalances in baseline characteristics within the subgroup.<sup>2</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=Limitations%3A-,Checkmate%209LA%20was%20not%20powered%20to%20detect%20differences%20in%20the,in%20baseline%20characteristics%20within%20the)

## Comparisons

<a id="opdivo-checkmate-057-017-survival"></a>

### Does Opdivo improve survival vs docetaxel in previously treated NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

> “NON-SQUAMOUS<sup>†</sup>
>
> Checkmate 057: OPDIVO (n=292) vs docetaxel (n=290)
>
> SUPERIOR OS<sup>1</sup>
> OPDIVO mOS: 12.2 months (95% CI: 9.7–15.0)
> Docetaxel mOS: 9.4 months (95% CI: 8.0–10.7)
> HR=0.73 (95% CI: 0.60–0.89); P=0.0015
>
> SQUAMOUS<sup>†</sup>
>
> Checkmate 017: OPDIVO (n=135) vs docetaxel (n=137)
>
> SUPERIOR OS<sup>1</sup>
> OPDIVO mOS: 9.2 months   (95% CI: 7.3–13.3)
> Docetaxel mOS: 6.0 months  (95% CI: 5.1–7.3)
> HR=0.59 (95% CI: 0.44–0.79); P=0.0002
>
> Both trials stopped early due to superior OS<sup>5,6</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy?tabKey=oivcheckmate057and017#:~:text=Checkmate%20057%3A%20OPDIVO%20%28n%3D292%29%20vs,stopped%20early%20due%20to%20superior)

> “<sup>†</sup>Results were based on the pre-specified interim analysis. Minimum follow-up of 11 months for Checkmate 017 and 13.2 months for Checkmate 057.<sup>1,7,8</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy?tabKey=oivcheckmate057and017#:~:text=were%20based%20on%20the%20pre%2Dspecified,and%2013.2%20months%20for%20Checkmate)

## Long-term results

<a id="opdivo-checkmate-057-017-five-year"></a>

### What is 5-year survival with Opdivo in previously treated NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

> “In a pooled analysis of Checkmate 057 and Checkmate 017, the median OS was 11.1 months (95% CI, 9.2–13.1) with OPDIVO IV vs 8.1 months (95% CI, 7.2–9.2) with docetaxel (HR=0.68, 95% CI, 0.59–0.78); the landmark 5-year OS rate with OPDIVO IV was 13.4% vs 2.6% with docetaxel.<sup>1,2</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy#:~:text=In%20a%20pooled%20analysis%20of,was%2013.4%25%20vs%202.6%25%20with)

> “Limitation: This pooled extended follow-up analysis was not statistically powered and cannot detect differences between treatment arms.”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy#:~:text=Limitation%3A%20This%20pooled%20extended%20follow%2Dup,detect%20differences%20between%20treatment%20arms.)

> “53% of OPDIVO responders* were alive at 5 years<sup>10†</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy?tabKey=oivcheckmate057and017#:~:text=53%25%20of%20OPDIVO%20responders%2A%20were%20alive%20at%205)

> “*OS was calculated from the time of response (CR/PR) for each responder.<sup>9</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy?tabKey=oivcheckmate057and017#:~:text=%2AOS%20was%20calculated%20from%20the%20time%20of%20response%20%28CR%2FPR%29%20for%20each)

## Related pages
- [Medical information: Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)
- [Indication](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/guidelines)
